Related Experiment Videos
CSF myelin basic protein in multiple sclerosis
Abstract:
Cerebrospinal fluid (CSF) from 221 patients with multiple sclerosis (MS) and 85 patients with other neurological disorders (OND) was examined using a competitive radioimmunoassay for myelin basic protein (MBP) immunoreactivity. MBP was found in 46 of 55 MS patients (84%) examined within six weeks of relapse but in only 11 of 85 patients (13%) with OND. There was a significant correlation between the concentration of MBP in the CSF and relapse severity in patients seen within four weeks of the onset of symptoms (p less than 0.01). Of 44 patients in remission, MBP was detected in 12, and these patients had a significantly higher tendency to subsequent relapse (p less than 0.05). In 72 patients with progressive disease the presence of MBP in the CSF reflected the confidence of clinical diagnosis. The results of this study suggest that measurement of MBP in the CSF gives an objective method of monitoring disease activity in patient with MS.
Insights
Measuring myelin basic protein (MBP) in cerebrospinal fluid (CSF) can objectively monitor multiple sclerosis (MS) disease activity. Elevated MBP levels correlate with relapse severity and predict future relapses in MS patients.
Area of Science:
- Neuroimmunology
- Clinical Neurology
Background:
- Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
- Accurate monitoring of disease activity is crucial for effective management of MS.
- Myelin basic protein (MBP) is a key component of myelin and a potential biomarker for demyelination.
Purpose of the Study:
- To investigate the utility of measuring myelin basic protein (MBP) in cerebrospinal fluid (CSF) as an objective marker for monitoring disease activity in patients with multiple sclerosis (MS).
Main Methods:
- Competitive radioimmunoassay was used to quantify MBP immunoreactivity in CSF samples.
- CSF was collected from 221 patients with MS and 85 patients with other neurological disorders (OND).
- MBP levels were analyzed in relation to disease status (relapse, remission, progressive disease) and clinical parameters.
Main Results:
- MBP was detected in 84% of MS patients during relapse versus 13% of OND patients.
- CSF MBP concentration correlated significantly with relapse severity within four weeks of symptom onset (p < 0.01).
- MBP detection in remission (12/44 patients) predicted a higher likelihood of subsequent relapse (p < 0.05).
Conclusions:
- CSF MBP measurement provides an objective method for monitoring disease activity in MS.
- MBP levels in CSF can serve as a biomarker for relapse severity and predict future disease activity.
- This assay aids in the clinical diagnosis and management of multiple sclerosis.